{
    "ticker": "TERN",
    "name": "Terns Pharmaceuticals, Inc.",
    "description": "Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver diseases, including nonalcoholic steatohepatitis (NASH) and liver cancer. Founded in 2018 and headquartered in San Francisco, California, Terns is committed to addressing significant unmet medical needs by leveraging its proprietary drug discovery platform and a deep understanding of liver biology. The company's lead product candidates include TERN-101, an oral FXR agonist aimed at treating NASH, and TERN-201, an oral THR-\u03b2 agonist designed for the treatment of NASH and other metabolic diseases. Terns has entered into strategic collaborations with leading pharmaceutical companies to enhance its research capabilities and expedite the development of its product pipeline. With a strong team of experienced professionals from the biopharmaceutical industry, Terns is dedicated to advancing its research and bringing effective therapies to market. The company's mission is to improve the lives of patients suffering from liver diseases through innovative science and a patient-centric approach.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "2018",
    "website": "https://www.ternspharma.com",
    "ceo": "Alfredo M. Asenjo",
    "social_media": {
        "twitter": "https://twitter.com/ternspharma",
        "linkedin": "https://www.linkedin.com/company/terns-pharmaceuticals"
    },
    "investor_relations": "https://ir.ternspharma.com",
    "key_executives": [
        {
            "name": "Alfredo M. Asenjo",
            "position": "CEO"
        },
        {
            "name": "Harlan W. Wachs",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Candidates",
            "products": [
                "TERN-101",
                "TERN-201"
            ]
        }
    ],
    "seo": {
        "meta_title": "Terns Pharmaceuticals, Inc. | Innovative Therapies for Liver Diseases",
        "meta_description": "Explore Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative therapies for liver diseases such as NASH and liver cancer.",
        "keywords": [
            "Terns Pharmaceuticals",
            "NASH",
            "Liver Cancer",
            "Biopharmaceuticals",
            "Liver Diseases",
            "TERN-101",
            "TERN-201"
        ]
    },
    "faq": [
        {
            "question": "What is Terns Pharmaceuticals known for?",
            "answer": "Terns Pharmaceuticals is known for developing innovative therapies for liver diseases, particularly NASH and liver cancer."
        },
        {
            "question": "Who is the CEO of Terns Pharmaceuticals?",
            "answer": "Alfredo M. Asenjo is the CEO of Terns Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Terns Pharmaceuticals headquartered?",
            "answer": "Terns Pharmaceuticals is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What are Terns Pharmaceuticals' main products?",
            "answer": "Terns Pharmaceuticals' main products include TERN-101 and TERN-201, both targeting liver diseases."
        },
        {
            "question": "When was Terns Pharmaceuticals founded?",
            "answer": "Terns Pharmaceuticals was founded in 2018."
        }
    ],
    "competitors": [
        "MRNA",
        "GILD",
        "BMY",
        "VIR"
    ],
    "related_stocks": [
        "AMGN",
        "ABBV",
        "REGN",
        "VRTX"
    ]
}